stoke therapeutics analyst coverage

Their average twelve-month price target is $59.00, suggesting a possible upside of 113.5%. TipRanks.com reports that BioNTech SE currently has 11 analysts offering 12-month price [â¦] On average, Wall Street analysts predict that. +70.16% Upside Potential. Our Pipeline. - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, announced that five abstracts related to the Company's work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2021 Annual â¦ ... COMPANIES UNDER COVERAGE. According to analysts' consensus price target of $62.00, Stoke Therapeutics has a forecasted upside of 121.0% from its current price of $28.06. Webull offers kinds of Stoke Therapeutics Inc stock information, including NASDAQ:STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to â¦ Health & Wellness Full-time employees are eligible to enroll in competitive benefit programs including medical, dental and vision insurance as well as life insurance and disability insurance. View the latest price targets for STOK. Chief Communications Officer. You can opt out at any time. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. The medicine increases gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke Therapeutics, Inc. announced positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data from a planned interim analysis of the multi-center, open-label Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome. STOKE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a.. Wedbush Adjusts Stoke Therapeutics PT to $48 From $47, Maintains Outperform Rating, Stoke Therapeutics' Q3 Loss Widens, Operating Expenses Rise. Stoke Therapeutics Reports Third Quarter Financial Results And Provides Business Updates Stoke Therapeutics Posts Q2 Loss Per Share $0.60 Stoke Therapeutics Says Had â¦ There are no approved disease modifying therapies for people living with Dravet syndrome. Stoke Therapeutics Inc STOK ... are generated using an algorithm that compares companies that are not under analyst coverage to peer â¦ The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. What is STOK's Earnings Per Share (EPS) forecast for 2021-2023? Stoke Therapeutics Shares Rise Following JPMorgan Upgrade, JPMorgan Upgrades Stoke Therapeutics to Overweight From Neutral; Price Target is $41, Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Showing records 1 - 20 ( 35 total ) Company: Stoke Therapeutics, Inc. Industry: Medical - Biomedical and Genetics. A secondary objective is to assess the efficacy as an adjunctive antiepileptic treatment with respect to the percentage change from baseline in convulsive seizure frequency over a 12-week treatment period. Currently, the analyst consensus on Stoke Therapeutics is a Strong Buy with an average price target of $70.40, implying a 29.3% upside from current levels. Adrian Krainer, Ph.D. Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Harpoon Therapeutics (HARP) Aug. 11, 2021 at 6:25 a.m. Stoke Therapeutics Inc. analyst estimates, including STOK earnings per share estimates and analyst recommendations. The current consensus among 8 contributing investment analysts is to buy stock in Stoke Therapeutics. proteins. According to analysts' consensus price target of $8.50, VYNE Therapeutics has a forecasted upside of 694.4% from its current price of $1.07. Analyst Debjit Chattopadhyay writes that Stoke is advancing an antisense oligonucleotide (ASO) platform, TANGO, to address a low-hanging fruit in genetic medicine: developing disease modifying therapies for indications â¦ Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. The following Wall Street research analysts have issued research reports on Stoke Therapeutics in the last twelve months: Canaccord Genuity, Cantor Fitzgerald, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, UBS Group AG, Wedbush, and Zacks Investment Research. Stoke Therapeutics, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). Move your mouse over past months for details. ANALYST BIOGRAPHY. Lightning quick coverage of all the news breaking right now on publicly traded companies. The average twelve-month price target for Stoke Therapeutics is $62.00 with a high price target of $76.00 and a low price target of $35.00. In a report issued on October 19, Goldman Sachs also initiated coverage with a Hold rating on the stock with a â¦ Is Stoke Therapeutics Stock a good buy in 2021, according to Wall Street analysts? PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or Enrollment and dosing in SWALLOWTAIL are underway. BEDFORD, Mass. What is STOK's forecast return on assets (ROA) for 2021-2024? STK-001 is an investigational new medicine for the treatment of Dravet syndrome. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $66.50 average price target, implying a 104.9% upside from current levels. Amount of Analyst Coverage Stoke Therapeutics has only been the subject of 2 research reports in the past 90 days. Analyst Price Target is. Stoke Webinar and Conference Call for Analysts and Investors Stoke will host a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Tuesday, September 21, 2021, to present the interim data from the Phase 1/2a MONARCH study of STK-001. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Here's what the top minds are saying and doing. Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. According to TipRanks.com, Gilson is a 4-star analyst with an average return of 20.6% and a 47.0% success rate. Stoke Therapeutics is proud to offer comprehensive employee benefits. Sign-up to receive the latest news and ratings for STOK and its competitors with Analyst Investor FAQs. About Phase 1/2a MONARCH Study (United States). According to TipRanks.com, Gilson is a 5-star analyst with an average return of 39.2% and a 67.7% success rate. BEDFORD, Mass. 'In addition to our progress in the clinic with STK-001, we continue to build a strong foundational understanding of the non-seizure aspects of the disease with data from our BUTTERFLY Observational study to help evaluate the potential of disease-modifying medicines. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. On December 8, 2019, Stoke Therapeutics (Nasdaq: STOK) presented new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome. Bottom 7%. Risk vs Reward. - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, announced that five abstracts related to the Company's work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2021 Annual Meeting, taking place December 3 - 7, 2021 in Chicago. 'At Stoke, our goal is to develop the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy,' said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021. View our earnings forecast for Stoke Therapeutics. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its earnings results on Tuesday, August, 10th. STOK Stoke Therapeutics $27.83 / -0.23 (-0.82%). Win Rate. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. Average Return. Stoke Therapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. Seattle company's cannabis candies could fuel boom in stock shares. 3. Analyst upgrades, downgrades, and commentary. According to TipRanks.com, Gilson is a 5-star analyst with an average return of 36.3% and a 66.0% success rate. Stoke Therapeutics MONARCH study in Dravet Syndrome Interim Analysis Presentation. -17.29%. Stoke Therapeutics, Inc. ... Several analyst firms initiated coverage on Rent The Runway with a huge upside to the company's price target. Win Rate. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA. Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. Currently, the analyst consensus on Gatos Silver is a Moderate Buy with an average price target of $16.31, a 27.0% upside from current levels. The MONARCH study is a Phase 1/2a open-label study of children and adolescents ages 2 to 18 who have an established diagnosis of Dravet syndrome and have evidence of a pathogenic genetic mutation in the SCN1A gene. A popular Seattle cannabis manufacturer recently announced the roll-out of an all-new line of premium infused edibles, marketed under the brand name "Goodies." BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 2, 2020-- â¦ Analyst Michelle Gilson initiated coverage with a Buy rating on Sigilon Therapeutics yesterday and set a price target of $62.00. The latest price target for . To see The Fly's full Street Research coverage, click here. #3471 out of 3555 analysts. #3329 out of 3555 analysts. Tewari has set a price target of $230. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). This price target is based on 8 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy.

John Barnes Icon Fifa 21, Nfl Customer Service Number, Riddles And Proverbs Examples, United Football League 2022, Motivational Quotes For Self, Qualicum Beach Obituaries, Wahl Waterless Cat Shampoo Side Effects, Memory Foam Carpet Pad Pros And Cons,